Assessing classifiers in terms of the partial area under the ROC curve

2013 ◽  
Vol 64 ◽  
pp. 51-70 ◽  
Author(s):  
Waleed A. Yousef
Keyword(s):  
2013 ◽  
Vol 32 (20) ◽  
pp. 3449-3458 ◽  
Author(s):  
Hua Ma ◽  
Andriy I. Bandos ◽  
Howard E. Rockette ◽  
David Gur

2011 ◽  
Vol 39 (1) ◽  
pp. 17-33 ◽  
Author(s):  
Gengsheng Qin ◽  
Xiaoping Jin ◽  
Xiao-Hua Zhou

2014 ◽  
Vol 57 (2) ◽  
pp. 304-320 ◽  
Author(s):  
Hua Ma ◽  
Andriy I. Bandos ◽  
David Gur

2019 ◽  
Vol 8 (1) ◽  
pp. 50-59 ◽  
Author(s):  
Andrew M. Smith ◽  
James Michael Lampinen ◽  
Gary L. Wells ◽  
Laura Smalarz ◽  
Simona Mackovichova

2019 ◽  
Vol 170 ◽  
pp. 61-69 ◽  
Author(s):  
Fan Cheng ◽  
Guanglong Fu ◽  
Xingyi Zhang ◽  
Jianfeng Qiu

2017 ◽  
Vol 37 (4) ◽  
pp. 627-642 ◽  
Author(s):  
Qingxiang Yan ◽  
Leonidas E. Bantis ◽  
Janet L. Stanford ◽  
Ziding Feng

2016 ◽  
Vol 10 (3) ◽  
pp. 1472-1495 ◽  
Author(s):  
Vanda Inácio de Carvalho ◽  
Miguel de Carvalho ◽  
Todd A. Alonzo ◽  
Wenceslao González-Manteiga

Mathematics ◽  
2021 ◽  
Vol 9 (21) ◽  
pp. 2826
Author(s):  
Manuel Franco ◽  
Juana-María Vivo

The burgeoning advances in high-throughput technologies have posed a great challenge to the identification of novel biomarkers for diagnosing, by contemporary models and methods, through bioinformatics-driven analysis. Diagnostic performance metrics such as the partial area under the ROC (pAUC) indexes exhibit limitations to analysing genomic data. Among other issues, the inability to differentiate between biomarkers whose ROC curves cross each other with the same pAUC value, the inappropriate expression of non-concave ROC curves, and the lack of a convenient interpretation, restrict their use in practice. Here, we have proposed the fitted partial area index (FpAUC), which is computable through an algorithm valid for any ROC curve shape, as an alternative performance summary for the evaluation of highly sensitive biomarkers. The proposed approach is based on fitter upper and lower bounds of the pAUC in a high-sensitivity region. Through variance estimates, simulations, and case studies for diagnosing leukaemia, and ovarian and colon cancers, we have proven the usefulness of the proposed metric in terms of restoring the interpretation and improving diagnostic accuracy. It is robust and feasible even when the ROC curve shows hooks, and solves performance ties between competitive biomarkers.


Sign in / Sign up

Export Citation Format

Share Document